Gilead Sciences announced a $5 billion acquisition of Tubulis, a specialty biopharma focused on antibody‑drug conjugate (ADC) technology, to broaden its oncology pipeline and strengthen its position in the rapidly growing ADC market.
The deal is structured with a $3.15 billion upfront cash payment and up to $1.85 billion in milestone payments, giving Gilead the option to earn additional cash as Tubulis’ clinical programs reach predefined development and commercial milestones.
Gilead will acquire Tubulis’ proprietary ADC platforms and two clinical‑stage assets: TUB‑040, a NaPi2b‑directed topoisomerase I inhibitor ADC in Phase Ib/II trials for platinum‑resistant ovarian cancer and non‑small‑cell lung cancer, and TUB‑030, a 5T4‑targeted ADC. The platforms include Tub‑tag, P5 conjugation, and Tubutecan linker‑payload technologies that aim to improve ADC stability and on‑tumor delivery while reducing off‑target toxicity.
Prior to the acquisition, Gilead and Tubulis had an exclusive option and license agreement established in December 2024, under which Gilead paid $20 million upfront and committed up to $415 million in milestones. Tubulis raised a Series C round of €344 million (≈$401 million) in October 2025, underscoring the company’s strong financial backing.
Gilead’s Q4 2025 earnings, released February 10 2026, showed total revenue of $7.9 billion, up 5% from the same period in 2024, driven by robust sales of its HIV and liver‑disease products. Non‑GAAP diluted EPS of $1.86 beat the consensus estimate of $1.83, a $0.03 margin, reflecting disciplined cost management amid modest revenue growth. The company guided 2026 product sales to $29.6 billion–$30 billion and non‑GAAP EPS to $8.45–$8.85, a range that sits at the lower end of analyst expectations and contributed to a temporary dip in investor sentiment.
"The agreement to acquire Tubulis is a significant milestone in Gilead's progress in oncology. The company brings a clinical‑stage candidate that is a potential new treatment for ovarian cancer, as well as a next‑generation ADC platform and a promising early pipeline," said Daniel O'Day, Chairman and CEO of Gilead. "Today's agreement follows a two‑year collaboration with Tubulis, which has given us strong conviction in their programs and research capabilities." Dominik Schumacher, CEO and co‑founder of Tubulis, added, "Joining Gilead allows us to build on this foundation within an organization that brings deep scientific expertise, global development capabilities, and the scale needed to translate innovation into medicines for patients worldwide." He also stated, "Based on our established collaboration, the Gilead team has seen the power of our platforms firsthand and how closely our teams align in scientific rigor, clinical development strategy, and commitment to patients."
The acquisition aligns with Gilead’s broader strategy of expanding its oncology portfolio through targeted, next‑generation therapies. By adding Tubulis’ advanced ADC platforms and early‑stage candidates, Gilead positions itself to compete more effectively against other biopharmaceuticals investing heavily in ADCs, while also diversifying its revenue streams beyond its core HIV and liver‑disease products. The deal complements recent acquisitions of Arcellx and Ouro Medicines, underscoring Gilead’s aggressive M&A approach to secure high‑potential assets before patent cliffs and competitive pressures erode its existing portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.